The HER2-targeted therapy zongertinib demonstrated clinical benefits for previously treated patients with advanced HER2-mutant non-small cell lung cancer – particularly those with specific HER2 ...

As previously reported, Cantor Fitzgerald analyst Carter Gould upgraded Regeneron (REGN) to Overweight from Neutral with a price target of $695, down from $800, as the analyst took over coverage ...

Regeneron (REGN) announced an expansion of its manufacturing capacity through a new agreement with Fujifilm Diosynth Biotechnologies to manufacture and supply bulk drug product of Regeneron’s ...

Regeneron signs $3 billion deal with FUJIFILM to expand biologics manufacturing in North Carolina, boosting U.S. capacity and ...

“Regeneron is an American success story, with over 80 percent of our workforce and assets in the U.S. and all of our FDA-approved medicines invented in our New York laboratories. Our innovative ...

Regeneron Pharmaceuticals has entered a new manufacturing and supply agreement with Fujifilm Diosynth Biotechnologies to broaden its capacity. Valued at more than $3bn, the partnership is set to ...

Regeneron Pharmaceuticals has a 52-week low of $525.99 and a 52-week high of $1,211.20. The firm has a market capitalization of $65.57 billion, a PE ratio of 15.67, a price-to-earnings-growth ...

(Reuters) -Regeneron Pharmaceuticals said on Tuesday it has signed a deal worth more than $3 billion with contract drug developer Fujifilm Diosynth, potentially doubling its U.S. manufacturing ...

(Reuters) -Regeneron Pharmaceuticals said on Tuesday it has signed a deal worth more than $3 billion with contract drug developer Fujifilm Diosynth, potentially doubling its U.S. manufacturing ...

New manufacturing and supply agreement with FUJIFILM Diosynth Biotechnologies in North Carolina will enable additional production of Regeneron’s biologic medicines and support high-paying jobs ...

has been inspired in no small part by the threat of sector-specific tariffs on pharmaceutical imports under the second Trump administration. To hear Regeneron’s CEO Leonard Schleifer ...